Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Stigma on Compliance to Medication in Functional Dyspepsia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03625674
Recruitment Status : Recruiting
First Posted : August 10, 2018
Last Update Posted : August 21, 2019
Sponsor:
Information provided by (Responsible Party):
Shengliang Chen, RenJi Hospital

Brief Summary:
To date, no study exists that evaluates whether functional dyspepsia patients experience stigma and how stigma may influence adherence. Thus, the investigators aim to evaluate the relationship between functional dyspepsia and stigma, and explore possible ways to improve treatment adherence.

Condition or disease Intervention/treatment Phase
Functional Gastrointestinal Disorders Adherence, Patient Behavioral: explanation when prescribing psychoactive medicine Not Applicable

Detailed Description:
Due to the functional but refractory nature of functional gastrointestinal diseases (FGIDs), large number of patients who suffer from FGIDs may not be able to fully understand their diagnosis, especially when they were told that they had no organic disease and their symptoms had a psychosomatic origin rather than a gastrointestinal one. Moreover, subjects with FGIDs have concerns and negative perceptions about medications, particularly in the presence of psychiatric comorbidity. Fearing of being labeled as insane or incapability, many patients with psychosomatic symptoms choose to conceal their illness to family, colleagues and doctors. These factors may affect willingness to initiate neuromodulator regimens and treatment adherence.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 220 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Impact of Stigma on Compliance to Medication in Functional Dyspepsia
Actual Study Start Date : September 1, 2017
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Indigestion

Arm Intervention/treatment
psychological and GI mechanisms
The patients in Group 1 were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Psychoactive medicine relieves FD symptoms through both psychological and GI mechanisms.
Behavioral: explanation when prescribing psychoactive medicine
explanation of the pathogenesis of FD and the mechanism of psychoactive medicine

psychological mechanism
The patients in Group 2 were told that: GI symptoms in FD are attributable to psychological mechanisms. Psychoactive medicine relieves FD symptoms through psychological mechanisms.
Behavioral: explanation when prescribing psychoactive medicine
explanation of the pathogenesis of FD and the mechanism of psychoactive medicine

GI mechanism
The patients in Group 3 were told that: GI symptoms in FD are attributable to GI mechanisms. Psychoactive medicine relieves FD symptoms through GI mechanisms.
Behavioral: explanation when prescribing psychoactive medicine
explanation of the pathogenesis of FD and the mechanism of psychoactive medicine

no explanation
The patients in Group 4 were not explained with the detailed mechanism of FD and psychoactive medicine
Behavioral: explanation when prescribing psychoactive medicine
explanation of the pathogenesis of FD and the mechanism of psychoactive medicine




Primary Outcome Measures :
  1. compliance of psychoactive medicine [ Time Frame: week8 ]
    Compliance is assessed by the medication possession ratio(MPR). The MPR is often defined as the sum of the days' supply of medication divided by the number of days between the first fill and the last refill plus the days' supply of the last refill. This calculation usually results in a ratio less than 1.0 if there are lapses in prescription refilling.


Secondary Outcome Measures :
  1. stigma scale [ Time Frame: week 0 ]
    Stigma is assessed by internalized stigma of mental illness (ISMI) scale and perceived stigma (PSS) scale adapted for FD. The ISMI is a 29-item self-report questionnaire with items ranked on a 4-point Likert Scale (strongly disagree = 1 to strongly agree = 4 points). An optional fifth subscale for stigma resistance was not used in this study. Higher scores indicate greater internalized stigma: scores ≤ 2 would be labeled as 'minimal stigma', scores 2 - 2.5 were labeled as 'mild stigma', scores 2.5 - 3 were labeled as 'moderate stigma' , scores > 3 were labeled as 'severe stigma'. The PSS is a 10-item questionnaire with items ranked on a 5-point Likert Scale (seldom = 1 to always = 5 points). Higher scores indicate greater levels of perceived stigma.

  2. dyspepsia symptom score [ Time Frame: week 2, week 4, week 6, week8 ]
    Participates' dyspeptic symptoms is assessed using the Leeds dyspepsia scale( LDQ), which is a reliable, valid and responsive outcome measure for quantifying the frequency and severity of dyspepsia symptoms. The LDQ contains eight items about epigastric pain, retro-sternal pain, regurgitation, nausea, vomiting, belching, early satiety and dysphagia with six grades for each item. LDQ scores of 0 - 4 were classified as very mild dyspepsia, 4 - 8 as mild dyspepsia, 9 -15 as moderate dyspepsia, and > 15 as severe or very severe dyspepsia.

  3. anxiety symptom scores [ Time Frame: week 2, week 4, week 6, week8 ]
    The anxiety condition is evaluated with the Generalized Anxiety Disorder Scale (GAD-7). The GAD-7 has good performance characteristics in screening generalized anxiety disorder and are feasible for use. The GAD-7 consists of 7 items on a four-point (0 - 3) scale. Scores of 0 to 4 can be regarded as absent of generalized anxiety disorder, , scores of 5 to 9 are suggestive of mild, scores of 10 to 14 indicate moderate, and scores of 15 or higher indicate severe generalized anxiety disorder.

  4. depression symptom scores [ Time Frame: week 2, week 4, week 6, week8 ]
    The depression condition is evaluated with the Patient Health Questionnaire Depression Scale (PHQ-9). The PHQ-9 is a 10-item questionnaire and has been proven to be a valid and efficient tool for screening depression. Scores of 0 to 4 can be regarded as none or minimal depression, scores of 5-9 as mild, scores of 10 to 14 are suggestive of moderate, scores of 15-19 as moderately severe, and scores of 20 or higher indicate severe depression.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18-70 years old;
  • met the ROME IV criteria for FD;
  • absence of abnormalities in physical examination, laboratory tests (including a routine blood test, blood glucose, and liver function examination), abdominal ultrasonography and upper GI endoscopy within 6 months;
  • absence of H. pylori infection;
  • Generalized Anxiety Disorder Scale (GAD-7) ≥ 1 or Patient Health Questionnaire Depression Scale (PHQ-9) ≥ 5

Exclusion Criteria:

  • any evidence of organic digestive diseases;
  • other FGIDs such as IBS;
  • severe psychological symptoms with GAD-7 ≥ 11 or PHQ-9 ≥15;
  • pregnancy or breastfeeding; recent myocardial infarction or cardiac arrhythmias;
  • previous gastric surgery;
  • use of PPIs, psychoactive drugs or other drugs that might affect gastric function within 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03625674


Locations
Layout table for location information
China
RenJiH Recruiting
Shanghai, China
Contact: Shengliang Chen    86-21-58752345    chenslmd@163.com   
Sponsors and Collaborators
RenJi Hospital

Layout table for additonal information
Responsible Party: Shengliang Chen, professor, chief physician, RenJi Hospital
ClinicalTrials.gov Identifier: NCT03625674     History of Changes
Other Study ID Numbers: RJYYXHNK-003
First Posted: August 10, 2018    Key Record Dates
Last Update Posted: August 21, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Diseases
Dyspepsia
Digestive System Diseases
Signs and Symptoms, Digestive
Signs and Symptoms